載入中
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.
前收盤價
US$2.08
+US$0.06 · +2.97%
盤中時間採用ET。市場資料可能有所延遲。
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.
日內區間
目前US$2.08
52週區間
目前US$2.08
盤中時間採用ET。市場資料可能有所延遲。
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.
日內區間
目前US$2.08
52週區間
目前US$2.08
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 2104.5萬 USD | 1.01億 USD | 9706.2萬 USD | 1.34億 USD | 2.07億 USD |
| 銷貨成本 | 966.1萬 USD | 1.86億 USD | 884.8萬 USD | — | 1.89億 USD |
| 毛利 | 1138.4萬 USD | −8538.2萬 USD | 8821.4萬 USD | 1.34億 USD | 1767.8萬 USD |
| 研究與開發 | 1.23億 USD | 2.09億 USD | 1.92億 USD | 2.1億 USD | 1.89億 USD |
| 銷售、一般及管理費用 | 5398.7萬 USD | 5741萬 USD | 5668.7萬 USD | 6103.3萬 USD | 5503.8萬 USD |
| 營業費用 | 1.57億 USD | 5961.5萬 USD | 2.4億 USD | 2.71億 USD | 5503.8萬 USD |
| 折舊和攤銷 | 966.1萬 USD | 884.1萬 USD | 884.8萬 USD | 847.2萬 USD | 831.5萬 USD |
| 營業利益 | −1.46億 USD | −1.45億 USD | −1.52億 USD | −1.38億 USD | −3736萬 USD |
| 淨利 | −1.43億 USD | −1.19億 USD | −1.3億 USD | −1.33億 USD | −3632.9萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$2.25
上漲空間 8.17%AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
